Tumor Suppression by Anti-Fibroblast Activation Protein Near-Infrared Photoimmunotherapy Targeting Cancer-Associated Fibroblasts
Cancers · 20.01.2024 · 16 (2) · 449
DOI: 10.3390/cancers16020449 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 20.01.2024. Verfasst von Raisa A Glabman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, National Cancer Institute, National Institutes of Health, National Cancer Institute.
Abstract (Originalsprache)
Cancer-associated fibroblasts (CAFs) constitute a prominent cellular component of the tumor stroma, with various pro-tumorigenic roles. Numerous attempts to target fibroblast activation protein (FAP), a highly expressed marker in immunosuppressive CAFs, have failed to demonstrate anti-tumor efficacy in human clinical trials. Near-infrared photoimmunotherapy (NIR-PIT) is a highly selective tumor therapy that utilizes an antibody-photo-absorbing conjugate activated by near-infrared light. In this study, we examined the therapeutic efficacy of CAF depletion by NIR-PIT in two mouse tumor models. Using CAF-rich syngeneic lung and spontaneous mammary tumors, NIR-PIT against FAP or podoplanin was performed. Anti-FAP NIR-PIT effectively depleted FAP+ CAFs, as well as FAP+ myeloid cells, and suppressed tumor growth, whereas anti-podoplanin NIR-PIT was ineffective. Interferon-gamma production by CD8 T and natural killer cells was induced within hours after anti-FAP NIR-PIT. Additionally, lung metastases were reduced in the treated spontaneous mammary cancer model. Depletion of FAP+ stromal as well as FAP+ myeloid cells effectively suppressed tumor growth in bone marrow chimeras, suggesting that the depletion of both cell types in one treatment is an effective therapeutic approach. These findings highlight a promising therapy for selectively eliminating immunosuppressive FAP+ cells within the tumor microenvironment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
- Department of Pathobiology and Diagnostic Investigation, College of Veterinary Medicine, Michigan State University, East Lansing, MI 48824, USA.
- Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21701, USA.
- Collaborative Protein Technology Resources, Office of Science and Technology Resources, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
ORCID-Profile: Raisa A Glabman, Laura L Bassel, Peter L Choyke, Noriko Sato
Förderung
- Intramural NIH HHS
- National Cancer Institute, National Institutes of Health
- National Cancer Institute
Zitieren
APA
Glabman, R. A., Olkowski, C. P., Minor, H. A., Bassel, L. L., Kedei, N., Choyke, P. L., & Sato, N. (2024). Tumor Suppression by Anti-Fibroblast Activation Protein Near-Infrared Photoimmunotherapy Targeting Cancer-Associated Fibroblasts. Cancers, 16(2), 449. https://doi.org/10.3390/cancers16020449
Vancouver
Glabman RA, Olkowski CP, Minor HA, Bassel LL, Kedei N, Choyke PL, et al. Tumor Suppression by Anti-Fibroblast Activation Protein Near-Infrared Photoimmunotherapy Targeting Cancer-Associated Fibroblasts. Cancers. 2024;16(2):449. doi:10.3390/cancers16020449
BibTeX
@article{Glabman2024,
author = {Glabman, Raisa A and Olkowski, Colleen P and Minor, Hannah A and Bassel, Laura L and Kedei, Noemi and Choyke, Peter L and Sato, Noriko},
title = {Tumor Suppression by Anti-Fibroblast Activation Protein Near-Infrared Photoimmunotherapy Targeting Cancer-Associated Fibroblasts},
journal = {Cancers},
year = {2024},
volume = {16},
number = {2},
pages = {449},
doi = {10.3390/cancers16020449}
}
EUVIMED